Wary pharma: AstraZeneca sours on UK

Wary pharma: AstraZeneca sours on UK

Up next

Delayed but not denied: justice for the Rohingyas

After decades of persecution, and seven years after the case was first brought before the UN’s highest court, judges ruled that Myanmar has committed genocide against the muslim minority. AI has facilitated new methods of cyber-crime, but for tech giants it has also created new o ...  Show more

Racing ahead: Anthropic’s big IPO

The leading AI lab is expected to raise over $80bn, the largest sum ever raised at an initial public offering. Where does this leave its rival OpenAI? The countries profiting from China and America’s battle for the world’s critical minerals. And why the colour of your rice might ...  Show more

Recommended Episodes

Wary pharma: AstraZeneca sours on UK
The Intelligence from The Economist

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Show more

AstraZeneca could spin off China business
FT News Briefing

AstraZeneca has drawn up plans to break out its China business, and France is challenging a German-led plan to build up Europe’s air defences. Plus, US businesses are cutting back on their investments in diversity and inclusion. 


Mentioned in this p ...

  Show more

AZ Good as it Gets?
Newscast

An AstraZeneca vaccine trial on children gets put on pause while a possible link with rare blood clots is investigated. And former Bank of England governor, Mark Carney, talks climate change, fintech and... should Adam sell his Bitcoin? Today’s Newscast was made by Sam Bonham wit ...  Show more